Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL222471 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL222472 | 1.00 | — | — | |
| SCHEMBL325385 | 0.97 | — | — | |
| SCHEMBL2223474 | 0.97 | — | — | |
| SCHEMBL1937488 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL18547503 | 0.92 | — | — | |
| Hydrochloric Acid SCHEMBL1972662 | 0.85 | — | — | |
| Hydrochloric Acid SCHEMBL1972660 | 0.85 | — | — | |
| Hydrochloric Acid SCHEMBL26613851 | 0.85 | — | — | |
| Hydrochloric Acid SCHEMBL1513767 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116881-A1 | KIF MODULATOR COMPOUNDS AND METHODS OF USE | IAMBIC THERAPEUTICS INC (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4466258-A1 | NEW BENZIMIDAZOLE PYRIDINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2024-11-27 | — | — | EP | disclosed |
| US-20240383875-A1 | Benzimidazole Pyridine Derivatives | HOFFMANN-LA ROCHE INC. (US) | 2024-11-21 | — | — | US | disclosed |
| CN-118591534-A | Novel benzimidazole pyridine derivatives | 豪夫迈·罗氏有限公司 | 2024-09-03 | — | — | CN | disclosed |
| US-20240124474-A1 | HER2 MUTATION INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2024-04-18 | — | — | US | disclosed |
| CN-117751115-A | Compounds, compositions, and methods of treating cancer | 热点治疗公司 | 2024-03-22 | — | — | CN | disclosed |
| US-20240092784-A1 | CONDENSED HETEROCYCLIC COMPOUND | NISSAN CHEMICAL CORPORATION (JP) | 2024-03-21 | — | — | US | disclosed |
| CN-112204029-B | Therapeutic compounds | 豪夫迈·罗氏有限公司 | 2024-03-01 | — | — | CN | disclosed |
| EP-4323358-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING CANCER | Hotspot Therapeutics, Inc. (US) | 2024-02-21 | — | — | EP | disclosed |
| CN-111417635-B | Pyrazolopyrimidines with anti-Respiratory Syncytial Virus (RSV) activity | 爱尔兰詹森科学公司 | 2024-01-02 | — | — | CN | disclosed |
| US-20140154240-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. | 2014-06-05 | — | — | US | disclosed |
| US-20140072554-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2014-03-13 | — | — | US | disclosed |
| US-8486938-B2 | Pyrazolo[1,5-a]pyrimidines for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| EP-2585467-A1 | PYRAZOLO [1, 5 -A]PYRIMIDINES AS ANTIVIRAL AGENTS | Gilead Sciences, Inc. (US) | 2013-05-01 | — | — | EP | disclosed |
| US-8309718-B2 | 4-pyrazolyl-N-arylpyrimidin-2-amines and 4-pyrazolyl-N-heteroarylpyrimidin-2-amines as janus kinase inhibitors | INCYTE CORPORATION (US) | 2012-11-13 | — | — | US | disclosed |
| US-20120003215-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2012-01-05 | — | — | US | disclosed |
| WO-2011163518-A1 | PYRAZOLO [1, 5 -A] PYRIMIDINES AS ANTIVIRAL AGENTS | GILEAD SCIENCES, INC. (US) | 2011-12-29 | — | — | WO | disclosed |
| EP-2220068-A1 | 4-PYRAZOLYL-N-ARYLPYRIMIDIN-2-AMINES AND 4-PYRAZOLYL-N-HETEROARYLPYRIMIDIN-2-AMINES AS JANUS KINASE INHIBITORS | Incyte Corporation (US) | 2010-08-25 | — | — | EP | disclosed |
| US-20090318405-A1 | 4-PYRAZOLYL-N-ARYLPYRIMIDIN-2-AMINES AND 4-PYRAZOLYL-N-HETEROARYLPYRIMIDIN-2-AMINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-12-24 | — | — | US | disclosed |
| WO-2009064835-A1 | 4-PYRAZOLYL-N-ARYLPYRIMIDIN-2-AMINES AND 4-PYRAZOLYL-N-HETEROARYLPYRIMIDIN-2-AMINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-05-22 | — | — | WO | disclosed |